Journal of Clinical Oncology, Vol 17, Issue 8
(August), 1999: 2334
© 1999 American Society for Clinical Oncology
Significance of Axillary Lymph Node Metastasis in Primary Breast Cancer
Ismail Jatoi,
Susan G. Hilsenbeck,
Gary M. Clark,
C. Kent Osborne
From the Department of Surgery, Brooke Army Medical Center, and Department of Medical Oncology, University of Texas Health Science Center at San Antonio, San Antonio, TX.
Address reprint requests to Ismail Jatoi, MD, PhD, Department of Surgery, Brooke Army Medical Center, 3851 Roger Brooke Dr, San Antonio, TX 78234-6200.
PURPOSE: Axillary lymph node status is the single most important prognostic variable in the management of patients with primary breast cancer. Yet, it is not known whether metastasis to the axillary nodes is simply a time-dependent variable or also a marker for a more aggressive tumor phenotype. The purpose of this study was to determine whether nodal status at initial diagnosis predicts outcome after relapse and therefore also serves as a marker of breast cancer phenotype.
PATIENTS AND METHODS: Survival experience after first relapse in 1,696 primary breast cancer cases was analyzed using Cox proportional hazards regression. The following explanatory variables and their first-order interactions were considered: number of axillary lymph nodes involved (zero v one to three v four or more), hormone receptor status (any estrogen receptor [ER] negativity v ER negativity/progesterone receptor positivity v other ER positivity), primary tumor size (< 2 cm v 2 to 5 cm v > 5 cm), site of relapse (locoregional v distant), disease-free interval (< 1.5 years v 1.5 to 3 years v > 3 years), adjuvant endocrine therapy (none v any), adjuvant chemotherapy (none v any), and menopausal status (pre-, peri-, or postmenopausal).
RESULTS: Axillary lymph node status, site of relapse, and hormone receptor status were all highly significant as main effects in the model. After adjustment for other variables, disease-free interval alone was only modestly significant but interacted with nodal status. After disease-free interval, hormone receptor status, and site of relapse were accounted for, survival after relapse was poorer in node-positive cases, when compared with node-negative cases. The hazard ratios for patients with one to three and four or more involved nodes were 1.2 (95% confidence interval [CI], 0.8 to 1.9) and 2.5 (95% CI, 1.8 to 3.4), respectively.
CONCLUSION: Patients with four or more involved nodes at initial diagnosis have a significantly worse outcome after relapse than node-negative cases, regardless of the duration of the disease-free interval. We conclude that nodal metastasis is not only a marker of diagnosis at a later point in the natural history of breast cancer but also a marker of an aggressive phenotype.
The opinions or assertions contained herein are the private views of the authors and are not to be construed as reflecting the views of the Departments of the Army, Air Force, or Defense.
 CiteULike  Complore  Connotea  Del.icio.us  Digg  Facebook  Reddit  Technorati  Twitter What's this?
This article has been cited by other articles:
|
|
|
|
 
M. Schmidt, A. Victor, D. Bratzel, D. Boehm, C. Cotarelo, A. Lebrecht, W. Siggelkow, J. G. Hengstler, A. Elsasser, M. Gehrmann, et al.
Long-term outcome prediction by clinicopathological risk classification algorithms in node-negative breast cancer--comparison between Adjuvant!, St Gallen, and a novel risk algorithm used in the prospective randomized Node-Negative-Breast Cancer-3 (NNBC-3) trial
Ann. Onc.,
February 1, 2009;
20(2):
258 - 264.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. C. Harrell, W. W. Dye, D. M.E. Harvell, M. Pinto, P. Jedlicka, C. A. Sartorius, and K. B. Horwitz
Estrogen Insensitivity in a Model of Estrogen Receptor Positive Breast Cancer Lymph Node Metastasis
Cancer Res.,
November 1, 2007;
67(21):
10582 - 10591.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Nakagawa, S. R. Martinez, Y. Goto, K. Koyanagi, M. Kitago, T. Shingai, D. A. Elashoff, X. Ye, F. R. Singer, A. E. Giuliano, et al.
Detection of Circulating Tumor Cells in Early-Stage Breast Cancer Metastasis to Axillary Lymph Nodes
Clin. Cancer Res.,
July 15, 2007;
13(14):
4105 - 4110.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Nakagawa, S. K. Huang, S. R. Martinez, A. N. Tran, D. Elashoff, X. Ye, R. R. Turner, A. E. Giuliano, and D. S.B. Hoon
Proteomic Profiling of Primary Breast Cancer Predicts Axillary Lymph Node Metastasis
Cancer Res.,
December 15, 2006;
66(24):
11825 - 11830.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. C. Harrell, W. W. Dye, D. C. Allred, P. Jedlicka, N. S. Spoelstra, C. A. Sartorius, and K. B. Horwitz
Estrogen receptor positive breast cancer metastasis: altered hormonal sensitivity and tumor aggressiveness in lymphatic vessels and lymph nodes.
Cancer Res.,
September 15, 2006;
66(18):
9308 - 9315.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Shinozaki, D. S.B. Hoon, A. E. Giuliano, N. M. Hansen, H.-J. Wang, R. Turner, and B. Taback
Distinct Hypermethylation Profile of Primary Breast Cancer Is Associated with Sentinel Lymph Node Metastasis
Clin. Cancer Res.,
March 15, 2005;
11(6):
2156 - 2162.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J E A Somner, J M J Dixon, and J S J Thomas
Node retrieval in axillary lymph node dissections: recommendations for minimum numbers to be confident about node negative status
J. Clin. Pathol.,
August 1, 2004;
57(8):
845 - 848.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. C. F. Leonard, M. Lind, C. Twelves, R. Coleman, S. van Belle, C. Wilson, J. Ledermann, I. Kennedy, P. Barrett-Lee, T. Perren, et al.
Conventional Adjuvant Chemotherapy Versus Single-Cycle, Autograft-Supported, High-Dose, Late-Intensification Chemotherapy in High-Risk Breast Cancer Patients: A Randomized Trial
J Natl Cancer Inst,
July 21, 2004;
96(14):
1076 - 1083.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Pittman, E. Huang, H. Dressman, C.-F. Horng, S. H. Cheng, M.-H. Tsou, C.-M. Chen, A. Bild, E. S. Iversen, A. T. Huang, et al.
Integrated modeling of clinical and gene expression information for personalized prediction of disease outcomes
PNAS,
June 1, 2004;
101(22):
8431 - 8436.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. V. Glinsky, T. Higashiyama, and A. B. Glinskii
Classification of Human Breast Cancer Using Gene Expression Profiling as a Component of the Survival Predictor Algorithm
Clin. Cancer Res.,
April 1, 2004;
10(7):
2272 - 2283.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Suga, Y. Yuan, M. Okada, N. Matsunaga, A. Tangoku, S. Yamamoto, and M. Oka
Breast Sentinel Lymph Node Mapping at CT Lymphography with Iopamidol: Preliminary Experience
Radiology,
February 1, 2004;
230(2):
543 - 552.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
V. Cocquyt, K. Moeremans, L. Annemans, P. Clarys, and S. Van Belle
Long-term medical costs of postmenopausal breast cancer therapy
Ann. Onc.,
July 1, 2003;
14(7):
1057 - 1063.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M P G Leers, R H M G Schoffelen, J G M Hoop, P H M H Theunissen, J W A Oosterhuis, H v. Bijl, A Rahmy, W Tan, and M Nap
Multiparameter flow cytometry as a tool for the detection of micrometastatic tumour cells in the sentinel lymph node procedure of patients with breast cancer
J. Clin. Pathol.,
May 1, 2002;
55(5):
359 - 366.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y. Nieto, S. Nawaz, R. B. Jones, E. J. Shpall, P. J. Cagnoni, P. A. McSweeney, A. Baron, C. Razook, S. Matthes, and S. I. Bearman
Prognostic Model for Relapse After High-Dose Chemotherapy With Autologous Stem-Cell Transplantation for Stage IV Oligometastatic Breast Cancer
J. Clin. Oncol.,
February 1, 2002;
20(3):
707 - 718.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. J. Goodwin, M. Ennis, K. I. Pritchard, M. E. Trudeau, J. Koo, Y. Madarnas, W. Hartwick, B. Hoffman, and N. Hood
Fasting Insulin and Outcome in Early-Stage Breast Cancer: Results of a Prospective Cohort Study
J. Clin. Oncol.,
January 1, 2002;
20(1):
42 - 51.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
